<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-7488</journal-id>
<journal-title><![CDATA[Ciencia en Desarrollo]]></journal-title>
<abbrev-journal-title><![CDATA[Ciencia en Desarrollo]]></abbrev-journal-title>
<issn>0121-7488</issn>
<publisher>
<publisher-name><![CDATA[Universidad Pedagógica y Tecnológica de Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-74882025000100009</article-id>
<article-id pub-id-type="doi">10.19053/01217488.v16.n1.2025.18625</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización Citogenética de pacientes con Leucemia Mieloide Aguda remitidos al laboratorio Biogenética Diagnóstica S.A.S, Bogotá, Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Cytogenetic Characterization of patients with Acute Myeloid Leukemia referred to the Biogenética Diagnóstica S.A.S laboratory, Bogotá, Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaona]]></surname>
<given-names><![CDATA[Geidi Catherine]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valbuena]]></surname>
<given-names><![CDATA[Duvan Sebastian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rubio Gómez]]></surname>
<given-names><![CDATA[Cladelis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cordón Sanchez]]></surname>
<given-names><![CDATA[Katherin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rondón-Lagos]]></surname>
<given-names><![CDATA[Milena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[Tunja ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Biogenética Diagnostica S.A.S.  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Coordinadora de Biogenética Diagnostica S.A.S.  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Genetista Biogenética Diagnostica S.A.S.  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[Tunja ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>16</volume>
<numero>1</numero>
<fpage>9</fpage>
<lpage>21</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-74882025000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-74882025000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-74882025000100009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La Leucemia Mieloide Aguda (LMA) y neoplasias relacionadas son enfermedades hematológicas agresivas causadas por la expansión clonal de blastocitos inmaduros en sangre periférica y médula ósea. Estos trastornos se caracterizan por ser heterogéneos biológica y clínicamente, lo cual influye directamente en la estratificación del riesgo y el pronóstico del paciente. Considerando lo anterior, la identificación de alteraciones cromosómicas y genéticas en neoplasias hematológicas malignas es crucial para el diagnóstico, pronóstico y clasificación del riesgo del paciente así como para la orientación de la terapia.  Objetivos: Establecer el tipo y la frecuencia de alteraciones cromosómicas de pacientes con LMA remitidos a un laboratorio de tercer nivel en Bogotá, Colombia.  Materiales y métodos: Se realizó un estudio descriptivo, transversal, en pacientes con diagnóstico de LMA, remitidos al laboratorio Biogenética Diagnóstica S.A.S. entre enero y junio de 2023. La información clínica de los pacientes fue recolectada mediante historias clínicas y bases de datos del laboratorio. Los datos se procesaron utilizando RStudio versión 4.3.1.  Resultados: Se analizaron un total de 60 casos, con una edad media de diagnóstico de 45,75 años. El mayor número de casos perteneció al subgrupo LMA-M3. Se observó alta prevalencia de alteraciones cromosómicas (53,3 % de los casos), siendo la trisomía del cromosoma 8 (16,66 %) la alteración más común, seguida de las translocaciones t(15;17)(q24;q21) (11,7 %) y t(8;21)(q22;q22) (6,66 %). Los cromosomas más alterados fueron los cromosomas 8 (23,3 %), 17 (18,33 %) y 15 (16,66 %). Solo el 21,6 % de los pacientes complementaron el análisis de cariotipo con FISH, de los cuales 9 presentaron resultados positivos para t(15;17) y t(8;21).  Conclusiones: El panorama de las alteraciones cromosómicas más frecuentes fue identificado en una cohorte de pacientes con LMA.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Acute myeloid leukemia (AML) and related neoplasms are aggressive hematologic diseases caused by clonal expansion of immature blasts in peripheral blood and bone marrow. These disorders are characterized by biological and clinical heterogeneity, which directly influences risk stratification and patient prognosis. Considering the above, the identification of chromosomal and genetic alterations in hematological malignancies is crucial for the diagnosis, prognosis and risk classification of the patient to better guide therapy.  Objectives: To establish the type and frequency of chromosomal alterations in patients with AML referred to a third level laboratory in Bogotá, Colombia.  Materials and Methods: A descriptive, cross-sectional study was carried out in patients with a diagnosis of AML, referred to the laboratory Biogenética Diagnóstica S.A.S. between January and June 2023. The patients' clinical information was collected through medical records and laboratory databases. The data were processed using RStudio version 4.3.1.  Results: A total of 60 cases were analyzed, with a mean age at diagnosis of 45.75 years. The largest number of cases belonged to the AML-M3 subgroup. A high prevalence of chromosomal alterations was observed in 53.3 % of the cases, with trisomy of chromosome 8 (16.66 %) being the most common alteration, followed by t(15;17)(q24;q21) (11.7%) and t(8;21)(q22;q22) (6.66%) translocations. The most altered chromosomes were chromosomes 8 (23.3%), 17 (18.33%) and 15 (16.66%). Only 21.6 % of the patients complemented the karyotype analysis with FISH, of which 9 presented positive results for t(15;17) and t(8;21).  Conclusions: The overview of the most frequent chromosomal alterations was identified in a cohort of AML patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Leucemia mieloide aguda]]></kwd>
<kwd lng="es"><![CDATA[análisis citogenético]]></kwd>
<kwd lng="es"><![CDATA[alteraciones cromosómicas]]></kwd>
<kwd lng="es"><![CDATA[FISH]]></kwd>
<kwd lng="en"><![CDATA[Acute myeloid leukemia]]></kwd>
<kwd lng="en"><![CDATA[cytogenetic analysis]]></kwd>
<kwd lng="en"><![CDATA[chromosomal alterations]]></kwd>
<kwd lng="en"><![CDATA[FISH]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinberg]]></surname>
<given-names><![CDATA[O. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Orazi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hasserjian]]></surname>
<given-names><![CDATA[R. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Foucar]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Duncavage]]></surname>
<given-names><![CDATA[E. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The International Consensus Classification of acute myeloid leukemia]]></article-title>
<source><![CDATA[Virchows Arch]]></source>
<year>2023</year>
<volume>482</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-37</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arber]]></surname>
<given-names><![CDATA[DA.]]></given-names>
</name>
</person-group>
<source><![CDATA[Acute Myeloid Leukemia. Hematopathology: A Volume in the Series: Foundations in Diagnostic Pathology]]></source>
<year>2018</year>
<page-range>429-466.e5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newell]]></surname>
<given-names><![CDATA[L. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in acute myeloid leukemia]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>375</volume>
<page-range>n2026</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017]]></article-title>
<source><![CDATA[J. Hematol. Oncol]]></source>
<year>2020</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="">
<collab>Cuenta de Alto Costo</collab>
<source><![CDATA[Leucemias en Colombia, ¿cuál es el panorama de la enfermedad en la población adulta?]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdul-Hamid]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classification of Acute Leukemia]]></article-title>
<source><![CDATA[Acute Leukemia - The Scientist's Perspective and Challenge]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khoury]]></surname>
<given-names><![CDATA[J. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Abla]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Akkari]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Alaggio]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Apperley]]></surname>
<given-names><![CDATA[J. F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2022</year>
<volume>36</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1703-19</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alaggio]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Amador]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Anagnostopoulos]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Attygalle]]></surname>
<given-names><![CDATA[A. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Araujo]]></surname>
<given-names><![CDATA[I. B. de O.]]></given-names>
</name>
<name>
<surname><![CDATA[Berti]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2022</year>
<volume>36</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1720-48</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nardo]]></surname>
<given-names><![CDATA[C. D. Di]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes]]></surname>
<given-names><![CDATA[J. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mutations in AML: prognostic and therapeutic implications]]></article-title>
<source><![CDATA[Hematology]]></source>
<year>2016</year>
<volume>2016</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>348-55</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walter]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Leucemia mieloide aguda]]></source>
<year>2011</year>
<publisher-name><![CDATA[Leukemia &amp; lymphoma society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kelemen]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms]]></article-title>
<source><![CDATA[Life]]></source>
<year>2022</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>109</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>[12]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Harbi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Aljurf]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mohty]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Almohareb]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S. O. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1]]></article-title>
<source><![CDATA[Blood Adv]]></source>
<year>2020</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>229-38</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>[13]</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia]]></article-title>
<source><![CDATA[N. Engl. J. Med]]></source>
<year>2013</year>
<volume>368</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2059-74</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>[14]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[J. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[H. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs]]></article-title>
<source><![CDATA[Blood Res]]></source>
<year>2022</year>
<volume>57</volume>
<page-range>S32-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>[15]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Auberger]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Tamburini-Bonnefoy]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Puissant]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug Resistance in Hematological Malignancies]]></article-title>
<source><![CDATA[Ïnt. J. Mol. Sci.]]></source>
<year>2020</year>
<volume>21</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>6091</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>[16]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Put]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Michaux]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Vandenberghe]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cytogenetic and molecular diagnosis of haematological malignancies: an overview of current techniques]]></article-title>
<source><![CDATA[Belg. J. Hematol]]></source>
<year>2014</year>
<numero>5</numero>
<issue>5</issue>
<page-range>3-11</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>[17]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DeAngelo]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Jabbour]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Advani]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Recent Advances in Managing Acute Lymphoblastic Leukemia]]></source>
<year>2020</year>
<numero>40</numero>
<issue>40</issue>
<page-range>330-42</page-range><publisher-name><![CDATA[Ed. Book]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>[18]</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bendari]]></surname>
<given-names><![CDATA[BM.]]></given-names>
</name>
<name>
<surname><![CDATA[Sraidi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Khoubila]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Haematological Malignancies: Overview of the Recent Progresses in Genetics]]></article-title>
<source><![CDATA[Cytogenetics - Classical and Molecular Strategies for Analysing Heredity Material]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>[19]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duque-Sierra]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Zapata-Cárdenas]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Duque-Ortega]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Donado-Gómez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Mejía]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características morfológicas, citogenéticas e inmunofenotípicas de los pacientes con leucemia mieloide aguda. Medellín, Colombia]]></article-title>
<source><![CDATA[ÇIMEL Cienc. Investig. Méd. Estud. Latinoam]]></source>
<year>2006</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>72-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>[20]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Madrid Muñoz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Cárdenas]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Colorado]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia de los pacientes adultos con leucemia mieloide aguda en el departamento de hematología del Hospital Pablo Tobón Uribe entre los años 2004 y 2010]]></article-title>
<source><![CDATA[Rev. Colomb. Hematol. Oncol]]></source>
<year>2017</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>40</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>[21]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuentesa]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rojasa]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ocqueteau]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bertin]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Sarmiento]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results of acute myeloid leukemia treatment. Analysis of 63 patients between 2010-2014]]></article-title>
<source><![CDATA[ev. Med. Chil]]></source>
<year>2015</year>
<volume>143</volume>
<numero>10,</numero>
<issue>10,</issue>
<page-range>1269-76</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>[22]</label><nlm-citation citation-type="">
<collab>Cancer Statistics Center</collab>
<source><![CDATA[American Cancer Society | Cancer Facts &amp; Statistics: Estimated new AML cases]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>[23]</label><nlm-citation citation-type="">
<collab>Leucemia mieloide aguda (LMA) en adultos</collab>
<source><![CDATA[Sociedad Americana del Cáncer]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B24">
<label>[24]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meng]]></surname>
<given-names><![CDATA[C. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Ismail]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ahid]]></surname>
<given-names><![CDATA[M. F. Md]]></given-names>
</name>
<name>
<surname><![CDATA[Zakaria]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytogenetic Profile of de novo Acute Myeloid Leukemia Patients in Malaysia]]></article-title>
<source><![CDATA[Ïnt. J. Biomed. Sci.]]></source>
<year>2013</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>[25]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Omer]]></surname>
<given-names><![CDATA[S. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Elamin]]></surname>
<given-names><![CDATA[B. K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of the different FAB sub type of Acute Myeloid Leukemia related to he-matological parameters in Sudanese]]></article-title>
<source><![CDATA[J. Hematol. Blood Disord]]></source>
<year>2017</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>[26]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pulte]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Redanie]]></surname>
<given-names><![CDATA[M. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Jansen]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Jeffreys]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups]]></article-title>
<source><![CDATA[Haematologica]]></source>
<year>2013</year>
<volume>98</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>222-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>[27]</label><nlm-citation citation-type="">
<source><![CDATA[Consenso basado en la evidencia para la definición de los indicadores de gestión del riesgo en los pacientes menores de 18 años con leucemias agudas (LLA Y LMA) - Cuenta de Alto Costo]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B28">
<label>[28]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[María]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Madrid Muñoz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Felipe]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Mauricio]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia de los pacientes adultos con leucemia mieloide aguda en el departamento de hematología del Hospital Pablo Tobón Uribe entre los años 2004 y 2010]]></article-title>
<source><![CDATA[Rev. Colomb. Hematol. Oncol]]></source>
<year>2017</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>40</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>[29]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mejía-Buriticá]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ocampo-Medina]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ospina-Ospina]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Regino-Agamez]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Hernández]]></surname>
<given-names><![CDATA[J. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización clínica y citogenética de una cohorte de pacientes con leucemia promielocítica aguda atendidos en un Hospital Universitario en Medellín, Colombia]]></article-title>
<source><![CDATA[Med. Lab]]></source>
<year>2022</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>273-86</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>[30]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vundinti]]></surname>
<given-names><![CDATA[B. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Korgaonkar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Dhangar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Jijina]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Shanmukhaiah]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency and pattern of chromosomal abnormalities in acute myeloid leukemia from Western India: A retrospective study]]></article-title>
<source><![CDATA[J. Cancer Res. Ther]]></source>
<year>2023</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>340-6</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>[31]</label><nlm-citation citation-type="book">
<source><![CDATA[Leucemia mieloide aguda: datos estadísticos sobre el cáncer]]></source>
<year></year>
<publisher-name><![CDATA[SEER]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<label>[32]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Oliver]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Caracterización de los pacientes con leucemia mieloide aguda en FOSCAL]]></source>
<year>2019</year>
<publisher-name><![CDATA[Universidad Autónoma de Bucaramanga UNAB]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<label>[33]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Padilha]]></surname>
<given-names><![CDATA[S. L.]]></given-names>
</name>
<name>
<surname><![CDATA[S. Souza]]></surname>
<given-names><![CDATA[E. J. dos]]></given-names>
</name>
<name>
<surname><![CDATA[Matos]]></surname>
<given-names><![CDATA[M. C. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Domino]]></surname>
<given-names><![CDATA[N. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná]]></article-title>
<source><![CDATA[Rev. Bras. Hematol. Hemoter]]></source>
<year>2015</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-7</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>[34]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Omer]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Elamin B]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of the different FAB sub type of Acute Myeloid Leukemia related to hematological parameters in Sudanese]]></article-title>
<source><![CDATA[J. Hematol. Blood Disord]]></source>
<year>2017</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>[35]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fröhling]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2006</year>
<volume>108</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3280-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>[36]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forman]]></surname>
<given-names><![CDATA[S. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Slovak]]></surname>
<given-names><![CDATA[M. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Arber]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[A. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival]]></article-title>
<source><![CDATA[Am. J. Clin. Pathol]]></source>
<year>2003</year>
<volume>119</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>672-80</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>[37]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahmood]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of AML classification: A single institution experience in a developing country]]></article-title>
<source><![CDATA[J. Hematop]]></source>
<year>2014</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-8</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>[38]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duque-Sierra]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características morfológicas, citogenéticas e inmunofenotípicas de los pacientes con leucemia mieloide aguda. Medellín, Colombia]]></article-title>
<source><![CDATA[CIMEL]]></source>
<year>2006</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>72-7</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>[39]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[C. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia]]></article-title>
<source><![CDATA[Genes Cancer]]></source>
<year>2011</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>95</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>[40]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaikh]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytogenetic abnormalities in acute myeloid leukaemia patients]]></article-title>
<source><![CDATA[J. Ayub Med. Coll. Abbottabad]]></source>
<year>2020</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-7</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>[41]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Çaliskan]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chromosomal Anomalies in Bone Marrow Samples of Patients Diagnosed with Hematological Cancer: FISH Results of 109 Cases from one Center]]></article-title>
<source><![CDATA[Aegean J. Med. Sci.]]></source>
<year>2022</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>44-50</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>[42]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Awan]]></surname>
<given-names><![CDATA[U. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytogenetic abnormalities in patients with hematological malignancies in Lahore city, Pakistan]]></article-title>
<source><![CDATA[Braz. J. Biol]]></source>
<year>2021</year>
<volume>83</volume>
</nlm-citation>
</ref>
<ref id="B43">
<label>[43]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schoch]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis]]></article-title>
<source><![CDATA[Br. J. Haematol]]></source>
<year>1997</year>
<volume>99</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>605-11</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>[44]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hemsing]]></surname>
<given-names><![CDATA[HA. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Hovland]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Tsykunova]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Reikvam]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trisomy 8 in acute myeloid leukemia]]></article-title>
<source><![CDATA[Expert Rev. Hematol]]></source>
<year>2019</year>
<volume>12</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>947-58</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>[45]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shoket]]></surname>
<given-names><![CDATA[S N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical profile of acute myeloid leukemia in North India and utility of nontransplant measures in its management]]></article-title>
<source><![CDATA[Indian J. Med. Paediatr. Oncol]]></source>
<year>2019</year>
<volume>40</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>S44-53</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>[46]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mrozek]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytogenetic, Molecular Genetic, and Clinical Characteristics of Acute Myeloid Leukemia With a Complex Karyotype]]></article-title>
<source><![CDATA[Semin. Oncol]]></source>
<year>2008</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>365-77</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>[47]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruserud]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Reikvam]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Hatfield]]></surname>
<given-names><![CDATA[K. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kittang]]></surname>
<given-names><![CDATA[A. O.]]></given-names>
</name>
<name>
<surname><![CDATA[Hovland]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications]]></article-title>
<source><![CDATA[J. Biomed. Biotechnol]]></source>
<year>2011</year>
<volume>2011</volume>
</nlm-citation>
</ref>
<ref id="B48">
<label>[48]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Luthra]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Konoplev]]></surname>
<given-names><![CDATA[S. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Medeiros]]></surname>
<given-names><![CDATA[L. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations]]></article-title>
<source><![CDATA[Mod. Pathol]]></source>
<year>2008</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1029-36</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>[49]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arber]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2016</year>
<volume>127</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2391-405</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>[50]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Döhner]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2022</year>
<volume>140</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1345-77</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>[51]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heuser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ofran]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Boissel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Brunet Mauri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Crad-dock]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Janssen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upt]]></article-title>
<source><![CDATA[Annals of Oncology]]></source>
<year>2020</year>
<volume>31</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>697-712</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>[52]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schoch]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Haferlach]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Haase]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Fonatsch]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Löffler]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Schlegelberger]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2001</year>
<volume>112</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>118-26</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>[53]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stölzel]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Mohr]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Oelschlägel]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Bochtler]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Berdel]]></surname>
<given-names><![CDATA[W. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Karyotype complexity and prognosis in acute myeloid leukemia]]></article-title>
<source><![CDATA[Blood Cancer Journal]]></source>
<year>2016</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B54">
<label>[54]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Der Holt]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Breems]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Beverloo]]></surname>
<given-names><![CDATA[H. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Van Den Berg]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Burnett]]></surname>
<given-names><![CDATA[A. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Sonneveld]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial]]></article-title>
<source><![CDATA[British Journal of Haematology]]></source>
<year>2007</year>
<volume>136</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-105</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
